Home > Cardiology > ESC 2022 > Allopurinol disappoints in ALL-HEART

Allopurinol disappoints in ALL-HEART

Presented By
Prof. Isla Shelagh Mackenzie, University of Dundee, UK
Conference
ESC 2022
Trial
ALL-HEART
The findings from the randomised, prospective ALL-HEART study show that allopurinol, a medicine commonly used to treat gout, did not reduce composite primary endpoint events, including non-fatal myocardial infarction (MI), non-fatal stroke, or cardiovascular death, in patients with ischaemic heart disease. The ALL-HEART (ISRCTN32017426) study results were presented by Prof. Isla Shelagh Mackenzie (University of Dundee, UK) [1]. Preclinical and observational data have suggested that allopurinol, a xanthine oxidase inhibitor involved in oxidative stress signalling and commonly prescribed as a treatment for gout, might confer cardiovascular benefits. "The importance of serum uric acid levels, which can be reduced by allopurinol, in cardiovascular disease is controversial, and there have been different reports over the years of how important they may be," Prof. Mackenzie explain...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on